Seaport Therapeutics October 2024 Series B Funding Round

Seaport Therapeutics, a clinical-stage biopharmaceutical company, has raised $225 million in an oversubscribed Series B funding round. Led by General Atlantic, other participants include T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and existing investors such as ARCH Venture Partners and Sofinnova Investments. The funds will advance Seaport’s pipeline of neuropsychiatric medicines, focusing on addressing depression and anxiety. The Glyph™ platform, pivotal in improving drug bioavailability, plays a key role in this innovation. The company aims to progress clinical trials, including those for its lead candidate, SPT-300, targeting major depressive disorder.